Standard BioTools Inc.
LAB
$1.19
-$0.08-6.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.56% | -86.03% | -64.53% | -40.99% | 31.14% |
| Total Depreciation and Amortization | -3.17% | 31.21% | 64.31% | 597.70% | 481.06% |
| Total Amortization of Deferred Charges | -9.14% | -- | -201.80% | -152.94% | -123.37% |
| Total Other Non-Cash Items | 3,338.62% | -57.23% | -74.73% | -83.36% | -98.41% |
| Change in Net Operating Assets | 10.22% | -1,380.58% | -897.69% | -161.93% | -36.51% |
| Cash from Operations | -14.37% | -231.40% | -196.35% | -106.15% | -18.25% |
| Capital Expenditure | -385.32% | -195.13% | -43.99% | 4.29% | 34.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.49% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 315.96% | 302.64% | -36.00% | -79.04% | 144.17% |
| Cash from Investing | -79.77% | 1,694.60% | 340.67% | 127.38% | 769.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -435.28% | -2,933.70% | -1,033.49% | -- | -- |
| Issuance of Common Stock | 122.25% | 150.30% | 169.68% | 165.15% | -2.81% |
| Repurchase of Common Stock | -112.81% | -637.42% | -587.84% | -631.40% | -332.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | 95.66% |
| Cash from Financing | -245.77% | -1,407.06% | -708.08% | -922.19% | -111.41% |
| Foreign Exchange rate Adjustments | -3,970.00% | -2,408.82% | -342.02% | -68.75% | 96.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.56% | 490.01% | 583.59% | 89.01% | 108.35% |